Cepham Research Center, USA
Title: Efficacy of Furosap, a novel Trigonella foenum-graecum seed extract in enhancing testosterone level and improving sperm profile in male volunteers
Debasis Bagchi is the Chief Scientific Officer of Cepham Research Center, Piscataway, NJ and a Faculty in the Department of Pharmacological and Pharmaceutical Sciences at the University of Houston College of Pharmacy, Houston, TX. He served as the SVP of R&D of InterHealth Nutraceuticals, Benicia, CA, from 1998 to 2011 and then as Director of Innovation and Clinical Affairs of Iovate Health Sciences, Oakville, ON, till June 2013. He has received the Master of American College of Nutrition Award in October 2010. He is the Past President of American College of Nutrition, Clearwater, FL. He has 309 peer reviewed publications, 27 books and 18 patents to his credit.
Dietary fiber rich fenugreek (Trigonella foenum-graecum) seeds have exhibited cardioprotective, hypolipidemic and other health benefits. In our laboratories, we have developed Furosap, an innovative, patent-pending 20% protodioscin-enriched extract from fenugreek seeds, which effectively increased testosterone levels, and significantly improved sperm profile, mental alertness, cardiovascular health, mood, libido and quality of life in male volunteers. Testosterone has also been demonstrated to attenuate lean body mass and stronger bones. Institutional Review Board (IRB) and other regulatory approvals were obtained for our study. This one-arm, open-labeled study was conducted in 50 male volunteers (age: 35 to 65 years) over a period of 12 weeks to determine the efficacy of Furosap (500 mg/day/subject). This study examined the testosterone levels, sperm profile, sperm morphology, libido and erectile dysfunction, mood and mental alertness and broad spectrum safety parameters. Free testosterone levels were improved up to 46% in 90% of the study population. 85.4% of the study population showed improvements in sperm counts. Sperm morphology improved in 14.6% of volunteers. Majority of the subjects enrolled in the study demonstrated improvements in mental alertness and mood. Furthermore, cardiovascular health and libido were significantly improved. Extensive safety parameters were evaluated which included blood chemistry data. No significant changes were observed in serum lipid function, cholesterol, triglyceride, HDL and LDL levels, hemogram (CBC), hepatotoxicity, cardiotoxicity and nephrotoxicity. Overall, the results demonstrate that Furosap, enriched in 20% protodioscin, is safe and effective in attenuating testosterone levels, healthy sperm profile, mental alertness, cardiovascular health and overall performance in human subjects.